CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Icares Medicus Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Icares Medicus Inc
4F, No.16, Section 2, Sheng Yi Road
Phone: +886 36579530p:+886 36579530 ZHUBEI, 302  Taiwan Ticker: 66126612

Business Summary
Icares Medicus Inc is a Taiwan-based company mainly engaged in the authorization of high-end medical material surface treatment technology. The Company is also involved in the sale of surface treatment formulations and provision of customer surface treatment processing services, as well as the research and development, manufacture and sale of artificial lens and its implantation system. The Company's product revenue is mainly divided into three categories. The royalty income comes from the authorization of implantation/invasive high-end medical material surface treatment technology. The technical service income mainly includes implantation/invasive high-end medical surface treatment services, provision of medical coatings and foundry of artificial lens implantation systems. The sales of medical materials mainly include the sales of medical materials surface inspection equipment and other products. The Company distributes its products in domestic and overseas markets.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/202212/31/2021Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Group Chief Executive Officer Ih-HoungLoh 7/1/2019
Vice Chairman of the Board, Group Chief Research & Development Officer Wen-ChuTseng 7/1/2019 6/25/2019
Group Chief Financial Officer, Head of Finance & Accounting, Corporate Governance Officer Tan-LiChen 5/11/2022
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 27 (As of 12/31/2014)
Outstanding Shares: 33,963,900 (As of 6/30/2022)
Shareholders: 1,820
Stock Exchange: TPO
Fax Number: +886 36579533


Copyright © 2022 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, September 25, 2022